Compare AHMA & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | SCYX |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 51.1M |
| IPO Year | 2024 | 2014 |
| Metric | AHMA | SCYX |
|---|---|---|
| Price | $1.37 | $5.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 34.3K | ★ 109.4K |
| Earning Date | 05-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | $180.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.57 |
| 52 Week High | $39.50 | $6.09 |
| Indicator | AHMA | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 57.13 |
| Support Level | $1.03 | $4.65 |
| Resistance Level | $1.88 | $5.56 |
| Average True Range (ATR) | 0.10 | 0.37 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 21.43 | 41.30 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.